NCT06144346Recruiting
Metastases Directed Therapy for Oligometastatic Breast Cancer
Role of Metastases Directed Radiotherapy in Addition to Standard of Care Systemic Treatment in the Management of Extracranial Oligometastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 22 Nov 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 4 Nov 2023
- Start date
- 20 Sept 2023
- Primary completion date
- 19 Aug 2025
- Lead sponsor
- National Cancer Institute, Egypt
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06144346
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 20 Sept 2023 to the primary completion date, 19 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radiotherapy to affected site(s) in less than a year.
Other illness
- Active Connective tissue diseases (e.g Rheumatoid Arthritis).
- Progression to widespread metastatic disease
Other
- •.Pregnant and lactating women.
- Cases with brain metastasis
Who the study is looking for
- Female patients aged 18 to 70 years.
- Pathological evidence of breast cancer, any grade, any T stage.
- Radiological (at least) evidence of metastatic activity with maximum number of 5 extracranial lesions.
- Performance status ≤ 2
- No pre-existing conditions that may prohibit radiotherapy.
Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Cancer Institute Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.